Home   Business   Article

Subscribe Now

Metrion Biosciences celebrates 10th year with Sunday Times 100 Tech listing for growth




Metrion Biosciences is celebrating a listing in The Sunday Times 100 Tech, as one of Britain’s fastest-growing private technology companies, which will be celebrated in the company’s 10th anniversary party in the summer.

Metrion, a specialist preclinical contract research organisation (CRO) and leader in ion channel screening, provides preclinical drug discovery services to a growing network of major pharmaceutical companies and smaller drug discovery businesses in leading global markets, including Europe, the US and Asia.

Metrion listed in the Sunday Times 100. Dr Katie Puddefoot, Senior Scientist I in the lab. Picture: Keith HeppellPicture: Keith Heppell
Metrion listed in the Sunday Times 100. Dr Katie Puddefoot, Senior Scientist I in the lab. Picture: Keith HeppellPicture: Keith Heppell

The company’s services leverage more than a decade of specialist ion channel research, built on pioneering work to develop and use automated patch clamp technology in drug discovery. Its suite of advanced, proprietary assays and cell lines, available to customers via standard or bespoke research projects, provide high-quality data for applications including in vitro cardiac safety, high-throughput ion channel screening, phenotypic assays and neuroscience research using brain slice tissue and an array of primary neurones.

Metrion, which is based on Granta Park, offers “careful interpretation of experimental findings, providing strategic recommendations to support decision making to best inform screening strategy”.

The listing is great news for Lee Patterson, who became CEO of Metrion Biosciences in December.

At Metrion Biosciences are , from left, CSO Dr Eddy Stevens, CEO Lee Patterson, CFO Clare Ruttyand COO Dr Rob KirbyPicture: Keith Heppell
At Metrion Biosciences are , from left, CSO Dr Eddy Stevens, CEO Lee Patterson, CFO Clare Ruttyand COO Dr Rob KirbyPicture: Keith Heppell

Asked what the company’s priorities are in 2025, Lee said: “Our customers’ goals are our priorities so my focus will be on enhancing our capabilities, and ensuring we remain the first-choice partner for pharmaceutical and biotechnology companies worldwide. Innovation and scientific excellence will remain at the heart of what we do, and I am committed to fostering a culture where these principles so obviously thrive.

“Continuing to focus on the customer will enable us to build strong, collaborative relationships. By listening to, and understanding, the unique challenges and objectives of our customers we can deliver tailored solutions that accelerate their drug discovery programmes and help them achieve their goals.

“The highest standards of scientific integrity remain paramount in reflecting our dedication to our mission and values.

“From my very first interactions with Metrion, I was struck by the company’s unwavering dedication to its mission: empowering the success of customers’ research and development programmes. The emphasis on quality, innovation, and collaboration aligns perfectly with my personal values and professional experience.

Metrion listed in the Sunday Times 100. Dr Ray Tang, Senior Scientist II in the lab. Picture: Keith HeppellPicture: Keith Heppell
Metrion listed in the Sunday Times 100. Dr Ray Tang, Senior Scientist II in the lab. Picture: Keith HeppellPicture: Keith Heppell

“It is an honour to become part of a team with such a strong commitment to delivering world-class scientific solutions and exceptional customer service. I look forward to working with the exceptionally talented team here to build on Metrion’s legacy and to further solidify its position as a leading CRO in preclinical drug discovery.”

Meanwhile, the team has enjoyed its Sunday Times moment.

“All staff gathered for a small celebration on 17 January when the Sunday Times announced our listing,” Lee noted. “We will celebrate this fully at our summer party this year when we also celebrate 2025 being the 10th anniversary of Metrion’s excellence in preclinical drug discovery.”



This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More